Table 2.
Baseline patient demographics
| ESS(n=111) | Dupi-24 (n=143) | Statistics (ESS vs Dupi) |
Dupi-52 (n = 295) |
Statistics (ESS vs Dupi) | Oma-1 (n=72) | Statistics (ESS vs Oma) |
Oma-2 (n= 62) |
Statistics (ESS vs Oma) | Mepo(n=206) | Statistics (ESS vs Mepo) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 51.9 [±15.8] | 52 (39–61) | -- | 52.0 (42–63) | -- | 50.0 [±14.5] | NS | 49.0 [±11.9] | NS | 48.6 [±13.6] | NS |
| Men (%) | 59 (53.2%) | 88 (62.0%) | NS | 184 (62.4%) | NS | 47 (65.3%) | NS | 39 (62.9%) | NS | 139 (67%) | NS |
| Asthma (%) | 68 (61.3%) | 82 (57.0%) | NS | 176 (59.7%) | NS | 42 (58.3%) | NS | 38 (61.3%) | NS | 140 (68%) | NS |
| AERD (%) | 37 (33.3 %) | 46 (32.0%) | NS | 76 (25.8%) | NS | 16 (22.2%) | NS | 24 (38.7%) | NS | 45 (22%) | NS |
| ≥1 previous ESS (%) | 66 (59.4%) | 99 (69.0%) | NS | 173 (58.6%) | NS | 39 (54.1%) | NS | 22 (35.5%) | (p=0.002) | 206 (100%) | (p<0.0001) |
| NPS (0–8) | ---- | 5.64 [±1.23] | ---- | 6.18 [±1.10] | ---- | 6.2 [±1.0] | ---- | 6.4 [±0.9] | ---- | 5.4 [±1.2] | ---- |
| LK polyp score (0–4) | 4.0 [±0.0] | 4.0 [±0.0]* | NS | 4.0 [±0.0]* | NS | 4.0 [±0.0]* | NS | 4.0 [±0.0]* | NS | 4.0 [±0.0]* | NS |
| Lund-Mackay CT total score (0–24) | 18.7 [±4.2] | 18.55 [±4.55] | NS | 18.12 [±2.00] | NS | ---- | ---- | ---- | ---- | ---- | ---- |
| SNOT-22 total score (mean±SD) | 56.1 [±19.6] | 48.0 [±20.16] | p=0.002 | 51.0 [±4.67] | p<0.001 | 59.8 [±19.7] | NS | 59.2 [±20.5] | NS | 63.7 [±17.6] | p<0.001 |
| Sniffin Sticks (mean±SD) (n=48) | 14.6 [±7.4] | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| SIT-40 score (mean±SD) (n=4) | 23.3 [±12.5] | 14.68 [±8.66] | NS | 13.53 [±2.75] | NS | 12.8 [±7.9] | NS | 12.8 [±7.6] | NS | ---- | ---- |
LEGEND:--- = comparisons were unable to be made due to unavailable data; ESS = Endoscopic sinus surgery; Dupi-24= Dupilumab Liberty NP SINUS-24; Dupi-52= Dupilumab Liberty NP SINUS-52; Mepo = mepolizumab-SYNAPSE; Oma-1 = Omalizumab POLYP-1; Oma-2 = Omalizumab POLYP-2; SNOT-22 = Sinonasal outcome test 22; NPS = Nasal polyp score; AERD = Aspirin exacerbated respiratory disease; LK = Lund-Kennedy; PROM = patient reported outcome measure; SIT-40 = Smell identification test-40; NS=Not significant;
*
based on clinical trial inclusion criteria of NPS≥5 with minimum of 2 on each sides by definition means all patients are LK-NP of 4